A single item for overall side effect impact: Association with clinician-reported adverse events and global health
GP5 is associated with both clinician- and patient-reported symptoms, suggesting its validity and usefulness as part of comprehensive tolerability assessment of cancer trials.
Authors
- Jessica Roydhouse (ORCID: https://orcid.org/0000-0002-8025-5841)
- Anne Zola (ORCID: https://orcid.org/0000-0001-7111-1515)
- Monique Breslin (ORCID: https://orcid.org/0000-0002-8135-3136)
- John Devin Peipert (ORCID: https://orcid.org/0000-0001-5762-7881)
- Melanie Calvert (ORCID: https://orcid.org/0000-0002-1856-837X)
- Gita Thanarajasingam
- Mary Lou Smith
- David Cella
- Ethan Basch
Institutions
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of Tasmania (AU)
- Mayo Clinic in Arizona (US)
- Research Advocacy Network (US)
- NIHR Birmingham Biomedical Research Centre (GB)
Publication Details
- Journal
- Clinical Trials
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1177/17407745251405412
- Primary Topic
- Pain Management and Placebo Effect
- Type
- article
- Field-Weighted Citation Impact
- 0.00